Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer

This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with metastatic esophageal cancer or gastroesophageal junction cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as cixutumumab, find tumor cells and help kill them. Giving paclitaxel with or without cixutumumab may kill more tumor cells.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.



  • biological : cixutumumab
  • drug : paclitaxel
  • other : laboratory biomarker analysis
  • other : pharmacological study

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Deryn Warner 6507232876

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: